Ranking by Regions
United States
Canada
Mexico
Brazil
Chile
Germany
United Kingdom
France
Spain
Netherlands
Sweden
Italy
Switzerland
Poland
Finland
China
Japan
South Korea
Hong Kong
Singapore
Indonesia
India
Malaysia
Taiwan
Thailand
Australia
New Zealand
Israel
Saudi Arabia
Turkey
Russia
South AfricaRanking by categories
As of January 22, 2025, Galapagos NV (GLPG) has a market cap of $1.58 billion USD. According to our data, Galapagos NV is ranked No.4523 in global market value.
| Year | Market Cap | %Change |
|---|---|---|
| Jan 22, 2025 | $1.58 B |
-12.98%
|
| Dec 31, 2024 | $1.81 B |
-32.35%
|
| Dec 29, 2023 | $2.68 B |
-8.40%
|
| Dec 30, 2022 | $2.92 B |
-19.50%
|
| Dec 31, 2021 | $3.63 B |
-44.30%
|
| Dec 31, 2020 | $6.52 B |
-52.14%
|
| Dec 31, 2019 | $13.63 B |
125.45%
|
| Dec 31, 2018 | $6.05 B |
-2.15%
|
| Dec 29, 2017 | $6.18 B |
46.07%
|
| Dec 30, 2016 | $4.23 B |
2.08%
|
| Dec 31, 2015 | $4.14 B |
239.71%
|
| Dec 31, 2014 | $1.22 B |
-12.02%
|
| Dec 31, 2013 | $1.39 B |
-0.33%
|
| Dec 31, 2012 | $1.39 B |
100%
|
| Name | Market Cap | Market cap difference | Regions |
|---|---|---|---|
 Gilead Sciences
GILD
|
$115.95 B |
0.002 M
|
USA
|
 Vertex Pharmaceuticals
VRTX
|
$110.22 B |
0.001 M
|
USA
|
 Regeneron Pharmaceuticals
REGN
|
$74.73 B |
1.236 B
|
USA
|
 Biogen
BIIB
|
$20.80 B |
0.000 M
|
USA
|
 Amgen
AMGN
|
$146.98 B |
0.004 M
|
USA
|
 Incyte
INCY
|
$13.95 B |
-0.000 M
|
USA
|
 Sarepta Therapeutics
SRPT
|
$11.09 B |
0.000 M
|
USA
|
 Alnylam Pharmaceuticals
ALNY
|
$34.38 B |
-0.000 M
|
USA
|
 bluebird bio
BLUE
|
$76.22 M |
0.000 M
|
USA
|
 CRISPR Therapeutics
CRSP
|
$3.77 B |
-0.000 M
|
Switzerland
|
 Editas Medicine
EDIT
|
$0.11 B |
-0.000 M
|
USA
|
 Intellia Therapeutics
NTLA
|
$1.12 B |
0.000 M
|
USA
|
 Moderna
MRNA
|
$14.82 B |
-0.000 M
|
USA
|
 BioMarin Pharmaceutical
BMRN
|
$11.82 B |
0.000 M
|
USA
|
 Sangamo Therapeutics
SGMO
|
$0.24 B |
-0.000 M
|
USA
|
| Market Cap | = | GLPG Stock Price | * | GLPG Shares Outstanding |
| = | $23.93 | * | 65.90 M | |
| = | $1.58 B |